Equilibre BioPharmaceuticals Corp.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2022 | $6 M | No. 3 | $2 to $10 million | equity | SEC | |
| Jan 2022 | $16 M | No. 2 | $10 to $50 million | equity | SEC | |
| Nov 2020 | $26 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Equilibre BioPharmaceuticals Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2022).
SEC Form D · Dec 2022
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Dec 2022
That is all the official record says: Equilibre BioPharmaceuticals Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Equilibre BioPharmaceuticals Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 14 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher M. Thorn | Executive officer | Dec 2022 |
| Philip A. Barach | Executive officer | Dec 2022 |
| Steven N. Gordon | Executive officer | Dec 2022 |
| Samuel Waksal | Executive officer | Jan 2022 |
| Steven Gordon | Executive officer | Jan 2022 |
| Sam Waksal | Executive officer | Nov 2020 |
| Christina A. Ramirez | Director | Dec 2022 |
| Christopher M. Thorn | Director | Dec 2022 |
| David A. Friedman | Director | Dec 2022 |
| Francois A. Maisonrouge | Director | Dec 2022 |
| Peter M. Simon | Director | Dec 2022 |
| Philip A. Barach | Director | Dec 2022 |
| Steven N. Gordon | Director | Dec 2022 |
| David Friedman | Director | Jan 2022 |
| Francois Maisonrouge | Director | Jan 2022 |
| Joel Marcus | Director | Jan 2022 |
| Peter Simon | Director | Jan 2022 |
| Philip Barach | Director | Jan 2022 |
| Samuel Waksal | Director | Jan 2022 |
| Steven Gordon | Director | Jan 2022 |